Daphnetin has been developed as an oral medicine for treatment of coagulation disorders and rheumatoid arthritis in China, but its in vitro metabolism remains unknown. In the present study, the UDP-glucuronosyltransferase (UGT) conjugation pathways of daphnetin were characterized. Two metabolites, 7-O (M-1) and 8-O (M-2) mono-glucuronide daphnetin were identified by liquid chromatography/mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR) when daphnetin was incubated respectively with liver microsomes from human (HLM), rat (RLM), minipig (PLM) and human intestinal microsomes (HIM) in the presence of uridine-5'-diphosphoglucuronic acid (UDPGA). Screening assays with 12 human recombinant UDP-glucuronosyltransferases (UGTs) demonstrated that the formations of M-1 and M-2 were almost exclusively catalyzed by UGT1A9 and UGT1A6, while M-1 was formed to a minor extent by UGT1A3, 1A4, 1A7, 1A8 and 1A10 at high substrate concentration. Kinetics studies, chemical inhibition, and correlation analysis were used to demonstrate that human UGT1A9 and UGT1A6 were major isoforms involved in the daphnetin glucuronidations in HLM and HIM. By in vitro-in vivo extrapolation of the kinetic data measured in HLM, the hepatic clearance and the corresponding hepatic extraction ratio were estimated to be 19.3 ml/min/kg body weight and 0.93, respectively, suggesting that human clearance of daphnetin via the glucuronidation is extensive. Chemical inhibition of daphnetin glucuronidation in HLM, RLM and PLM showed large species difference although the metabolites were formed similarly among the species. In conclusion, the UGT conjugation pathways of daphnetin were fully elucidated and its C-8 phenol group was more selectively catalyzed by UGTs than the C-7 phenol.
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Introduction
Benzo-α-pyrones skeleton-containing courmarins are widely distributed in the plant kingdom and have a general application in food, drug and cosmetic products (Egan et al., 1990) . As one of coumarin derivatives, daphnetin (7, 8-dihydroxycoumarin) has exhibited broad biological activities, such as anti-inflammatory (Fylaktakidou et al., 2004) , antioxidant (Fylaktakidou et al., 2004) , antimicrobial (Cottiglia et al., 2001 ) and anti-malarial (Huang et al., 2006) effects as well as the protein kinase inhibitory activities (Yang et al., 1999) .
Clinically, daphnetin not only has been developed as an oral medicine for treatment of coagulation disorders and rheumatoid arthritis in China since 1980s
(http://app1.sfda.gov.cn/datasearch/face3/base.jsp), but also been used as a folk medicine to treat lumbago and reduce fever in Turkey (Yesilada et al., 2001) . Moreover, recent studies demonstrated that daphnetin can act as a potent antiproliferative and differentiation-inducing agent in human renal cell carcinoma (Finn et al., 2004) .
The pharmacokinetic study of daphnetin in rats after intravenous administration shows that the elimination of daphnetin is rapid with a t 1/2 of about 15 min and poor bioavailability; however, the responsible mechanisms for the pharmacokinetic properties are unclear (Qu et al., 1983) . Structurally, daphnetin contains a catechol group on its basic skeleton, which could be susceptible to the metabolism by phase II enzymes, such as UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and catechol-O-methyltransferases (COMTs) (Antonio et al., 2002; Antonio et al., 2003) . 5 (Antonio et al., 2002; Antonio et al., 2003) ; protocatechuic aldehyde, a antasthmatic agent (Liu et al., 2008) ; and PH-302, an inhibitor of nitric oxide synthase (Loureiro et al., 2006) .
On the other hand, it is noted by the previous studies that 7-hydroxycoumarin and 4-methylumbelliferone, the structural analogs of daphnetin, are substrates for the UGTs with high affinity (Uchaipichat et al., 2004; Wang, 2006) . Therefore, it is necessary to understand the role of glucuronidation in the metabolic elimination of daphnetin since the glucuronidation of most benzo-α-pyrones has been demonstrated as a primary route of clearance (Tukey and Strassburg, 2000) .
Glucuronidation, the major phase II conjugation reaction, accounts for > 35% of all phase II drug metabolites (Kiang, 2005) . Nineteen human UGT isoforms have been identified, and these UGTs have been classified into two families (UGT1 and UGT2) based on their sequence identity (Tukey and Strassburg, 2000; Mackenzie et al., 2005) . Many UGTs have had broad and overlapping substrate specificities, though the specificity of UGT isoforms to certain substrates is known (e.g., UGT1A1 for bilirubin, UGT1A4 for trifluoperazine, UGT1A6 for serotonin, UGT1A9 for propofol, and UGT2B7 for 3'-azido-3'-deoxythy-midine) (Court, 2005; Miners et al., 2006) . In addition, human UGTs are tissue-specific due to their differences in expression. For example, UGT1A7, 1A8, 2A1, and 1A10 are mainly expressed in extrahepatic tissues, though liver is generally recognized as the major site of glucuronidation (Fisher et al., 2001) . Notably, highly inter-individual variability and the differential UGT expression within different segments of the gut have been also reported (Strassburg et al., 1998 Guengerich (1989) and previous reports (Zhang et al., 2008) . Protein concentration was determined by using bovine serum albumin as the standard (Lowry et al., 1951 and Tris-HCl buffer (pH 7.4). After 10 min of incubation at 37°C, the reaction was terminated by the addition of 0.1 ml of methanol containing 0.3 μ g of internal standard
(7-hydroxycoumarin), followed by centrifugation at 20,000g for 10 minutes to obtain the supernatant for Ultra-Fast liquid chromatography spectrometry (UFLC) analysis. Control incubations without UDPGA or without substrate or without microsomes were performed to ensure that the metabolites produced were microsome-and UDPGA-dependent. A Shimadzu LC/MS-2010EV mass spectrometer (Kyoto, Japan) with an ESI interface was used to identify daphnetin and its metabolites (M-1 and M-2) operating in both negative and positive ion modes from m/z 100 to 1000. The detector voltage was set at +1.50 kV, and -1.55 kV for positive and negative ion detection, respectively. The curved desolvation line temperature (CDL) and the block heater temperature were both set at 250°C. Other MS detection conditions were set as follows: voltage, 4 kV; interface voltage, 40 V; nebulizing gas (N 2 ) flow was tuned to be 1.5 l/min and the drying gas (N 2 ) pressure was set at 0.06 MPa. Data processing was performed using the UFLC-MS Solution version 3.41 software.
In order to confirm these two metabolites are glucuronide compounds, 200 μ l glucuronidation incubation mixture (see above, but without D-saccharic acid 1,4-lactone) was incorporated into an equal volume of 0.15 M acetate buffer (pH 5.0) containing 1800
Fishman units of β -glucuronidase. After 2 h incubation at 37°C, the hydrolysis reaction was terminated by addition of 0.1 ml of cold methanol, followed by centrifugation at 20,000g for 
Biosynthesis metabolite and NMR spectrometry
The glucuronidation metabolites (M-1 and M-2) of daphnetin were biosynthesized and purified for structure elucidation and quantitative analysis. Enzymatic biosynthesis of M-1 and M-2 was conducted using RLM, because they resemble HLM in daphnetin metabolism.
In brief, 600 µM daphnetin was incubated with RLM (0.5 mg protein/ml), 0.1 M Tris-HCl pH 7.4, 10 mM MgCl 2 , Brij 58 (0.5 mg/mg protein), 10 mM D-saccharic acid 1,4-lactone, and 5 mM UDPGA in 100 ml of final incubations for 2 h at 37°C. The stock solution of daphnetin (60 mM) was prepared in methanol. The concentration of organic solvent in the final incubation was 1%. The reaction was terminated by transferring the vessel to an ice bath and cooling for 20 min. After the removal of protein by centrifugation at 20,000g for 15 min at 4°C, the combined supernatants were loaded on a SPE cartridge (C 18 , 1000 mg, Agela Technologies, USA), which was preconditioned by sequential washing with 5 ml methanol and 5 ml water containing 0.2% formic acid. After loading on the incubation material, the cartridge was washed with 15 ml water containing 0.2% formic acid. Then the trapped compounds were eluted with 5 ml methanol, and blown dry with nitrogen gas at 20°C. ml/min. The purity was greater than 99% for both metabolites by using UFLC-DAD detection.
The structures of metabolites M-1 and M-2 were determined by spectral methods including 2D-NMR such as HSQC, HMBC and NOESY. All experiments were recorded on a
Bruker AV-600 (Bruker, Newark, Germany). The purified metabolites of M-1 (2.6 mg) and M-2 (2.3 mg) were stored at -20°C before dissolving in DMSO-d 6 (Euriso-Top, Saint-Aubin, France) for NMR analysis. Chemical shifts were given on δ scale and referenced to tetramethylsilane (TMS) at 0 ppm for 1 H-(600 MHz) and 13 C-NMR (150 MHz).
Assay with recombinant UGTs
Daphnetin glucuronidation was measured in reaction mixtures containing recombinant human UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17. The incubations were carried out as shown above for the HLM study. Three substrate concentrations (10, 100 and 600 μ M) were used in this study: 600 and 100 μ M were the approximate concentration at V max , and K m value for HLM, respectively; 10 μ M was used to evaluate the catalytic activity of the UGT isoform(s) with the high affinity for daphnetin glucuronidation. All assays were conducted at 37°C for 60 min with the final protein concentration of 0.5 mg protein/ml. UFLC with DAD detection was used to monitor possible metabolites.
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Chemical inhibition studies
Daphnetin glucuronidation in pooled HLM, HIM, UGT1A6, and UGT1A9 were measured in the absence or presence of inhibitor (phenylbutazone or mefenamic acid).
Phenylbutazone is the potent inhibitor for UGT1As (Uchaipichat et al., 2006) and mefenamic acid is the potent inhibitor for UGT1A9 (Tachibana et al., 2005) . Daphnetin (100 μ M) was incubated in the absence or presence of either phenylbutazone (10-500 μ M) or mefenamic acid (1-50 μ M). All incubations were performed for 10 min using a protein concentration of 0.1 mg of protein/ml. The IC 50 , representing the inhibitor concentration that inhibits 50% of control activity, was determined by nonlinear curve fitting with Origin (Orgin Lab Corporation, Northampton, MA), as described previously (Zhang et al., 2009 ).
For comparison of the inhibitory effects of phenylbutazone and mefenamic acid among different species, several concentrations of phenylbutazone (50 μ M and 500 μ M) and mefenamic acid (10 μ M and 100 μ M) in pooled liver microsomes from human, rat and minipig were conducted to investigate their inhibitory effects on daphnetin glucuronidation.
Correlation analysis in HLM
Linear regression analysis was used to assess the correlation between the glucuronidation activity toward daphnetin and serotonin or propofol in microsomes from 14 individual human livers. The activity of UGT1A6-catalyzed serotonin glucuronidation and UGT1A9-catalyzed propofol glucuronidation was 1.27 to 3.05 nmol/min/mg and 0.25 to 2.20 nmol/min/mg of protein, respectively. The daphnetin and HLM concentrations were 100 μ M and 0.1 mg of protein/ml, respectively. The reaction mixture was incubated for 10 min at This article has not been copyedited and formatted. The final version may differ from this version. 
Quantitative analysis
The separation and quantification of daphnetin glucuronides by UFLC were carried out using a Shimadzu (Kyoto, Japan) Prominence ultra-fast liquid chromatography (UFLC)
Prediction of tissue clearances from in vitro data
The in vivo intrinsic clearances (CL' int ) of daphnetin glucuronidation in liver and intestine were scaled-up by the equation 1 (Obach et., al 1997 
where C mic is the microsomal protein concentration used in the incubation, the value of which is 0.1 mg/ml for both HIM and HLM, and LogP is the log of the octanol buffer (pH = 7.4) partition (P) coefficient of the daphnetin, the value of which is 1.2 according to the website (http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=5991). Therefore, the bound fraction of daphnetin to microsomal protein can be negligible in this study.
For evaluation of the magnitude of UGT conjugation pathways to the elimination of daphnetin, the hepatic clearance (CL H ) was predicted from the resulting estimated in vivo hepatic intrinsic clearance (CL' int,liver ) using equation 3 based on the well-stirred model
where f u,b is the fraction unbound of daphnetin in blood, Q H is hepatic blood flow, and Q H values of 20.7 ml/min/kg weight (Cubitt et al. 2009 ) were used. Fraction unbound of daphnetin in blood and plasma (f u,p ) were considered equivalent for extrapolation purposes, although it is acknowledged that some difference may occur. f u,p was obtained from the separate experiments using the ultrafiltration method (Taylor and Harker, 2006) at two concentrations (17.8 and 178 ng/ml) of daphnetin.
Results
Identification of daphnetin metabolites
Two new peaks were eluted at 4.0 (M-1) and 4.5 min (M-2) by UFLC, respectively when daphnetin (200 μ M) was incubated with HLM, HIM (data not shown), RLM or PLM (0.1 mg/ml) in the presence of UDPGA (Fig. 1) . The peaks were not detected in the control samples in the absence of UDPGA, daphnetin or microsomes (data not shown). The negative-ion mode was adopted for chemical identification because it is more sensitive than the positive-ion mode for daphnetin and its metabolites. Mass spectra were dominated by 
Chemical inhibition
The inhibitory effects of phenylbutazone and mefenamic acid on daphnetin glucuronidation in pooled HLM, HIM, UGT1A6 and UGT1A9 were evaluated. As shown in Table. 3, phenylbutazone inhibited potently the UGT activity for the formation of the metabolites in HLM, HIM, UGT1A6 and UGT1A9. Mefenamic acid appeared generally to be more potent in inhibition than phenylbutazone except for UGT1A6. Similar 
Kinetic characterization
The kinetic parameters of M-1 and M-2 production in HLM, HIM, RLM, PLM and the potent UGT isoforms (Table 3) 
Discussion
Most of hydroxycoumarin derivatives sharing their benzo-α-pyrones skeleton are good substrates of human UGTs (Tukey and Strassburg, 2000) . For example, 4-methylumbelliferone has been widely used as non-selective probes for evaluation of glucuronidation activities (UGT1A1, 1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7, 2B15 and 2B17) due to its high affinity for UGTs and turnover for the formation of the metabolite (Uchaipichat et al., 2004) . With respect to the catechol compounds, UGT1A6, UGT1A9 and UGT2B7 can be potentially involved in their glucuronidation (Antonio et al., 2003; Loureiro et al., 2006) . Daphnetin is the hydroxycoumarin derivative as well as the catechol-containing compound. In the present study, UGT1A9 and UGT1A6 were the most capable of catalyzing the glucuronidation of daphnetin at three substrate concentrations, but trace amount of daphnetin 7-O-glucuronide could be formed by UGT1A3, 1A4, 1A7, 1A8 and 1A10 (<20 pmol/min/ mg protein) at the high substrate concentrations (600 μ M) (Fig. 3) . The findings indicated that the C-8 phenolic group of daphnetin was more selectively catalyzed by UGTs compared with the C-7 phenol.
UGT1A6 and UGT1A9, which exhibited the highest activity towards daphnetin, are expressed in both the liver and intestine (Strassburg et al., 1998; Basu et al., 2004; . Many phenol-containing xenobiotics are substrates of UGT1A6 and UGT1A9, and significant overlap of substrate selectivity occurs (Ebner and Burchell, 1993; Uchaipichat et al., 2004) . The kinetic studies of daphnetin glucuronidation by UGT1A9 and UGT1A6
showed the similar V max /K m values between these two isoforms for M-1 formation, though the V max /K m values with UGT1A9 was higher than that of UGT1A6 for M-2 formation, which could be attributed to the relative low K m value with UGT1A9 (Table 2 ). In addition, the K m This article has not been copyedited and formatted. The final version may differ from this version. values in recombinant UGT1A9 and UGT1A6 were lower than those in HLM and HIM, it may due to 1) the difference of the single/multiple UGT nature between cDNA-expressed and microsomal samples; 2) the relative low fatty acid content in expression systems, since long-chain unsaturated fatty acids can act as potent competitive inhibitors of UGT1A9 (Rowland et al., 2008) ; 3) the involvement of other UGTs for the formation of M-1 at high substrate concentrations (UGT1A3 and UGT1A4 for HLM; UGT1A3, 1A4, 1A7, 1A8 and 1A10 for HIM; See Fig. 2) . The comparable kinetic profiles of UGT1A9 and UGT1A6 were also confirmed by the evidence of monophasic Eadie-Hofstee plots observed in HLM and HIM, which suggested that UGT1A9 and UGT1A6 play major roles in formation of daphnetin glucuronides in these two organs, though UGT1A9 showed marginally higher affinity than that of UGT1A6 (Table 2) . Moreover, the findings were also supported by the results of correlation analysis and the subsequent inhibition studies, high correlation between daphnetin glucuronides formation with propofol O-glucuronidation as well as serotonin O-glucuronidation was displayed in Fig. 4 , and the comparable inhibitory effects of phenylbutazone and mefenamic acid on human liver and intestine microsomes with similar IC 50 values can be seen from Table. 3. It should be noted that mefenamic acid is a known potent inhibitor of UGT1A9 and UGT2B7 in the literature (Tachibana et al., 2005; Gaganis et al., 2007) . Since UGT2B7 was not found to be involved in daphnetin glucuronidation, mefenamic acid can be served as selective inhibitors to UGT1A9 in this study. Altogether, in vitro UGT conjugation pathways of daphnetin in human liver and intestine were proposed in In the current study, the large inter-individual variability (57.9% CV for M-1 and 59.3%
for M-2) was observed in the liver samples from 14 donors, which would be attributed to the effect of age, sex, enzyme inducers (e.g., drugs, tobacco, and alcohol), and genetic polymorphism on the enzyme sources from different donors (Court, 2009) . In agreement with our data, the work by Court (2005) showed that UGT1A9-mediated propofol glucuronidation (CV = 55%) and UGT1A6-mediated serotonin glucuronidation (CV = 76%) were high variability within the human liver bank containing 54 individualities. Suffering from the large inter-individual variability in the hepatic glucuronidation of daphnetin, hence the different response to the pharmacokinetic and clinical outcomes within people after administration of daphnetin, can be also forecasted. Furthermore, interactions induced by daphnetin with dietary components and other compounds primarily catalyzed by UGT1A9 and UGT1A6
should be given attention in clinical applications.
IVIVE of the kinetic data for daphnetin glucuronidation in HLM and HIM was performed, and results showed that the in vivo intrinsic clearance in liver was markedly larger than that of in intestine (344 vs. 9.7 ml/min/kg body weight), which suggested that the liver might play a major role for daphnetin metabolic clearance via glucuronidation. The well-stirred model was constrained to predict the hepatic clearance in this study, considering that gut is a not single homogenous tissue like liver since intestinal UGTs are mainly expressed in intestinal mucosa, and the UGT activities are also not same in different region of intestine (Strassburg et al., 1998) . The predicted results showed that daphnetin was a high clearance molecule in vivo with the hepatic extraction ratio larger than 0.7, and most of the orally administered daphnetin might not reach the systemic circulation due to the significant first-pass hepatic metabolism. Therefore, given the high clearance of daphnetin by This article has not been copyedited and formatted. The final version may differ from this version. can play a role in pharmacological activity needs to be understood.
Two mono-glucuronide metabolites (M-1 and M-2) were detected in liver microsomes of all species, and HIM. However, no di-glucuronide was detected in all the microsomal samples, which may be caused by the steric hindrance of conjugation at one catecholic hydroxyl group from the conjugation at the other group as previously reported (Lautala et al., 2000) . The metabolic profiles and enzyme kinetic parameters can be used to evaluate the variation among species (Shiratani et al., 2008) . The inhibitory patterns are also very important for selection of animal model(s) suitable to investigation of the pharmacodynamics, toxicology, and pharmacokinetics of new chemical entities (Mano et al., 2008) . For further evaluation of daphnetin glucuronidation in HLM, RLM and PLM, the inhibition assays were conducted. The inhibition studies by phenylbutazone and mefenamic acid showed significant species difference (Fig. 3) , indicating that different UGT isozymes may afford to the glucuronidation of daphnetin among these species.
In conclusion, daphnetin is extensively glucuronidated in in vitro incubation systems in the presence of UDPGA. UGT1A9 and UGT1A6 are identified as the major isoforms for daphnetin glucuronidation in HLM and HIM. More studies on the biological activities of these glucuronide metabolites remain to be investigated. Our results confirmed the crucial role of UGT1A9 and UGT1A6 in the glucuronidation of catechol-containing compounds in human and further suggested that daphnetin might serve as a probe substrate for UGT1A6
and UGT1A9 to phenotype the UGTs in liver microsomes from human and animals.
